

SUPPLEMENTARY DATA

Anti-Alzheimer potential of *Tamarindus indica*: An *in vivo* investigation supported by *in vitro* and *in silico* approach

Abeer H. Elmaidomy^{1#}, Usama Ramadan Abdelmohsen^{2,3*#}, Faisal Alsenani⁴, Hanan F. Aly⁵, Shams Gamal Eldin Shams⁵, Eman A. Younis⁵, Kawkab A. Ahmed⁶, Ahmed M. Sayed⁷, Asmaa I. Owis¹, Naglaa Afifi¹, Dalia El Amir¹

¹Department of Pharmacognosy, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 62514, Egypt

²Department of Pharmacognosy, Faculty of Pharmacy, Minia University, Minia 61519, Egypt

³Department of Pharmacognosy, Faculty of Pharmacy, Deraya University, 7 Universities Zone, New Minia 61111, Egypt

⁴Department of Pharmacognosy, Faculty of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia

⁵Therapeutic Chemistry Department, National Research Centre (NRC), El-Bouth St., P.O. 12622 Cairo, Egypt

⁶Department of Pathology, Faculty of Veterinary Medicine, Cairo University, Giza, 12211, Egypt

⁷Department of Pharmacognosy, Faculty of Pharmacy, Nahda University, 62513, Beni-Suef, Egypt

*Corresponding author: Department of Pharmacognosy, Faculty of Pharmacy, Minia University, Minia 61519, Egypt, usama.ramadan@mu.edu.eg

Those authors are equally contributed

32 Abstract

33 *Tamarindus indica* Linn., (Tamarind, F. Fabaceae) is one of the most widely consumed fruits in
34 the world. The crude extract and different fractions of *T. indica* (*n*-hexane, dichloromethane, ethyl
35 acetate, and *n*-butanol) were evaluated *in vitro* against DPPH scavenging, and AchE inhibition
36 activities. Results showed that dichloromethane, and ethyl acetate fractions showed the highest
37 antioxidant activities, with 84.78, and 86.96% DPPH scavenging using 0.10 ug/mL. While the *n*-
38 hexane, dichloromethane, and ethyl acetate fractions, inhibited AchE activity in a dose dependent
39 manner, where *n*-hexane fraction showed the highest inhibition at 20 µg/mL. The results were
40 confirmed by subjecting *n*-hexane, dichloromethane, and ethyl acetate fractions *in vivo* in
41 regression of the neurodegenerative features of Alzheimer's dementia in Aluminum-intoxicated
42 rat model. Phytochemical investigation for those three fractions afforded two new diphenyl ether
43 derivatives compounds **1-2**, along with five known ones. The structures of the isolated compounds
44 had been confirmed using 1D, 2D NMR and HRESIMS analyses. The isolated compounds were
45 subjected to extensive *in silico*-based investigation to putatively highlight the most probable
46 compounds responsible for the anti-Alzheimer activity of *T. indica*. Inverse docking that was
47 followed by molecular dynamics simulation (MDS) and binding free energy (ΔG) estimation
48 suggested both compounds **1** and **2** to be promising AchE inhibitors. The results presented in this
49 study may provide potential dietary supplements for the management of Alzheimer disease.

50 **Keywords:** Alzheimer; AchE; *in vitro*; docking; *in silico*; *Tamarindus indica*.

51

52

53

54

List of Contents

- Figure S1.** ^1H NMR spectrum of compound **1** measured in $\text{DMSO-}d_6$ at 400 MHz
- Figure S2.** DEPT-Q NMR spectrum of compound **1** measured in $\text{DMSO-}d_6$ at 100 MHz
- Figure S3.** ^1H NMR spectrum of compound **2** measured in $\text{DMSO-}d_6$ at 400 MHz
- Figure S4.** DEPT-Q NMR spectrum of compound **2** measured in $\text{DMSO-}d_6$ at 100 MHz
- Figure S5.** ^1H NMR spectrum of compound **3** measured in $\text{CD}_3\text{OD-}d_4$ at 400 MHz
- Figure S6.** DEPT-Q NMR spectrum of compound **3** measured in $\text{CD}_3\text{OD-}d_4$ at 100 MHz.
- Figure S7.** ^1H NMR spectrum of compound **4** measured in $\text{CD}_3\text{OD-}d_4$ at 400 MHz
- Figure S8.** DEPT-Q NMR spectrum of compound **4** measured in $\text{CD}_3\text{OD-}d_4$ at 100 MHz
- Figure S9.** ^1H NMR spectrum of compound **5** measured in $\text{CD}_3\text{OD-}d_4$ at 400 MHz
- Figure S10.** DEPT-Q NMR spectrum of compound **5** measured in $\text{CD}_3\text{OD-}d_4$ at 100 MHz
- Figure S11.** ^1H NMR spectrum of compound **6** measured in $\text{DMSO-}d_6$ at 400 MHz
- Figure S12.** DEPT-Q NMR spectrum of compound **6** measured in $\text{DMSO-}d_6$ at 100 MHz
- Figure S13.** ^1H NMR spectrum of compound **7** measured in $\text{CDCl}_3\text{-}d$ at 400 MHz
- Figure S14.** DEPT-Q NMR spectrum of compound **7** measured in $\text{CDCl}_3\text{-}d$ at 100 MHz




Figure S1. ^1H NMR spectrum of compound **1** measured in $\text{DMSO-}d_6$ at 400 MHz




Figure S2. DEPT-Q NMR spectrum of compound **1** measured in DMSO- d_6 at 100 MHz



Figure S3. ^1H NMR spectrum of compound **2** measured in $\text{DMSO}-d_6$ at 400 MHz




Figure S4. DEPT-Q NMR spectrum of compound **2** measured in DMSO- d_6 at 100 MHz




Figure S5. ^1H NMR spectrum of compound **3** measured in $\text{CD}_3\text{OD}-d_4$ at 400 MHz




Figure S6. DEPT-Q NMR spectrum of compound **3** measured in CD₃OD-*d*₄ at 100 MHz.




Figure S7. ^1H NMR spectrum of compound **4** measured in $\text{CD}_3\text{OD}-d_4$ at 400 MHz




Figure S8. DEPT-Q NMR spectrum of compound **4** measured in $\text{CD}_3\text{OD}-d_4$ at 100 MHz




Figure S9. ^1H NMR spectrum of compound **5** measured in $\text{CD}_3\text{OD}-d_4$ at 400 MHz




Figure S10. DEPT-Q NMR spectrum of compound **5** measured in $\text{CD}_3\text{OD}-d_4$ at 100 MHz




Figure S11. ^1H NMR spectrum of compound **6** measured in $\text{DMSO}-d_6$ at 400 MHz




Figure S12. DEPT-Q NMR spectrum of compound **6** measured in DMSO- d_6 at 100 MHz




Figure S13. ¹H NMR spectrum of compound **7** measured in CDCl₃-d at 400 MHz




Figure S14. DEPT-Q NMR spectrum of compound **7** measured in CDCl_3-d at 100 MHz

57 **Methods**

58 ***Prediction of the Potential Protein Targets of the annotated Compounds in T. indica crude*** 59 **extract**

60 By performing inverse docking against all human proteins in the Protein Data Bank (PDB;
61 <https://www.rcsb.org/>), potential protein targets for the annotated compounds in *T. indica* crude
62 extract were identified. This task was accomplished with the help of the idTarget platform
63 (<http://idtarget.rcas.sinica.edu.tw/>). This structural-based screening software uses a unique
64 docking approach known as divide-and-conquer docking, in which it adaptively builds small
65 overlapping grids to constrain the searching space on protein surfaces, allowing it to run a large
66 number of accurate docking experiments in a shorter amount of time. The data were collected as a
67 list of binding affinity scores, organized from the most negative to the least negative. To identify
68 the optimal targets for each identified molecule in *T. indica* crude extract, we used a binding
69 affinity score of -7 kcal/mol as a cut-off number. Accordingly, AchE (PDB: 4EY6) was selected
70 as an Alzheimer-related target for compounds 1 and 2.

71 ***Molecular Docking***

72 AutoDock Vina software was used in all molecular docking experiments¹. All annotated
73 compounds were docked against the AchE crystal structure (PDB codes: 4EY6)². The binding site
74 was determined according to the enzyme's co-crystallized ligand. The co-ordinates of the grid box
75 were: x = -10.77; y = -42.48; z = 30.56. The size of the grid box was set to be 10 Å. Exhaustiveness
76 was set to be 24. Ten poses were generated for each docking experiment. The top-scoring poses
77 were selected for MDS. Docking poses were analyzed and visualized using Pymol software¹.

78 ***Molecular Dynamics Simulation***

Desmond v. 2.2 software was used for performing MDS experiments³⁻⁵. This software applies the OPLS-2005 force field. Protein systems were built using the System Builder option, where the protein structure was checked for any missing hydrogens, the protonation states of the amino acid residues were set (pH = 7.4), and the co-crystallized water molecules were removed. Thereafter, the whole structure was embedded in an orthorhombic box of TIP3P water together with 0.15 M Na⁺ and Cl⁻ ions in 20 Å solvent buffer. Afterward, the prepared systems were energy minimized and equilibrated for 10 ns. For proteinligand complexes, the top-scoring poses were used as a starting points for simulation. Desmond software automatically parameterizes inputted ligands during the system building step according to the OPLS force field. For simulations performed by NAMD⁶, the protein structures were built and optimized by using the QwikMD toolkit of the VMD software. The parameters and topologies of the compounds 1 and 2 were calculated using the VMD plugin Force Field Toolkit (ffTK). Afterward, the generated parameters and topology files were loaded to VMD to readily read the protein–ligand complexes without errors and then conduct the simulation step.

Binding Free Energy Calculations

Binding free energy calculations (ΔG) were performed using the free energy perturbation (FEP) method⁷. This method was described in detail in the recent article by Kim and coworkers⁷. Briefly, this method calculates the binding free energy $\Delta G_{\text{binding}}$ according to the following equation: $\Delta G_{\text{binding}} = \Delta G_{\text{Complex}} - \Delta G_{\text{Ligand}}$. The value of each ΔG is estimated from a separate simulation using NAMD software. All input files required for simulation by NAMD can be prepared by using the online website Charmm-GUI (<https://charmm-gui.org/?doc=input/afes.abinding>, accessed on 23 June 2021). Subsequently, we can use these files in NAMD to produce the required simulations using the FEP calculation function in NAMD. The equilibration (5 ns long) was achieved in the

102 NPT ensemble at 300 K and 1 atm (1.01325 bar) with Langevin piston pressure (for “Complex”
103 and “Ligand”) in the presence of the TIP3P water model. Then, 10 ns FEP simulations were
104 performed for each compound, and the last 5 ns of the free energy values were measured for the
105 final free energy values⁷. Finally, the generated trajectories were visualized and analyzed using
106 VMD software.

107

108 **References**

- 109 1. D. Seeliger and B. L. de Groot, *Journal of computer-aided molecular design*, 2010, **24**,
110 417-422.
- 111 2. F. J. Moy, P. K. Chanda, J. M. Chen, S. Cosmi, W. Edris, J. S. Skotnicki, J. Wilhelm and R.
112 Powers, *Biochemistry*, 1999, **38**, 7085-7096.
- 113 3. K. J. Bowers, D. E. Chow, H. Xu, R. O. Dror, M. P. Eastwood, B. A. Gregersen, J. L.
114 Klepeis, I. Kolossvary, M. A. Moraes and F. D. Sacerdoti, 2006.
- 115 4. S. Release, *Maestro-Desmond Interoperability Tools*, Schrödinger, New York, NY, 2017.
- 116 5. V. Maestro, *Schrödinger, LLC: New York, NY, USA*, 2009.
- 117 6. J. C. Phillips, R. Braun, W. Wang, J. Gumbart, E. Tajkhorshid, E. Villa, C. Chipot, R. D.
118 Skeel, L. Kale and K. Schulten, *Journal of computational chemistry*, 2005, **26**, 1781-1802.
- 119 7. S. Kim, H. Oshima, H. Zhang, N. R. Kern, S. Re, J. Lee, B. Roux, Y. Sugita, W. Jiang and
120 W. Im, *Journal of chemical theory and computation*, 2020, **16**, 7207-7218.

121

122